glucose solution had no marked affect.[26]
There are currently no pharmacokinetic data available for
clevidipine in patients with renal or hepatic impairment.
However, hepatic or renal dysfunction are considered unlikely
to affect clevidipine elimination as the drug is metabolized
mainly in the blood and extravascular tissues (section 3.2).[3]
The potential for clevidipine to interact with drugs metabolized
via cytochrome P450 (CYP) enzymes appears to be low. Data from
an in vitro study[27]suggest that neither clevidipine nor its carboxylic acid metabolite are likely to inhibit or induce CYP enzymes to